ERBB2 and neoplasm: We showed that, besides patients with highly HER2-positive scores, this approach is able to identify more patients who may benefit from T-DXd therapy, including those with low (IHC 1+, IHC 2+/ISH−) or IHC >0 to <1+ HER2 scores, a heterogeneous tumor with respect to single-cell HER2 expression, or a high density of tumor-infiltrating lymphocytes (TILs).